GILD stock forecast, quote, news & analysis

Key Takeaways

• GILD shares traded at $130.21 as of July 31, 2026, reflecting a modest decline of approximately 0.8% over the trailing 30-day period, with the stock effectively range-bound ahead of its upcoming Q2 earnings report.
• Gilead is scheduled to report second-quarter results on August 4, 2026, with analysts expecting a headline loss of roughly $7.09 per share driven by an estimated $11.2 billion IPR&D charge tied to the Arcellx acquisition and other pending deals.
• Underlying operational performance remains solid: the HIV franchise — anchored by Biktarvy and the newly launched injectable PrEP therapy Yeztugo — continues to deliver double-digit growth, with 2026 HIV sales guidance raised to approximately 8%.
• Analyst sentiment is broadly constructive, with 26 of 29 covering analysts rating GILD a Buy and a consensus price target of $159, though a July downgrade from Leerink Partners highlighted competitive risks in the HIV prophylaxis market.
• Investors are closely watching the Q2 print for clarity on pipeline progress, oncology expansion via Trodelvy, and whether core revenue momentum can offset near-term acquisition-related accounting headwinds.

Current Market Snapshot

Gilead Sciences stock has traded in a relatively narrow band over the last 30 days, hovering between roughly $126 and $137 before settling at $130.21 on July 31. With a beta of just 0.32, GILD has exhibited significantly lower volatility than the broader market, consistent with its profile as a large-cap biopharmaceutical holding. The stock currently changes hands at approximately 18 times trailing earnings and offers a quarterly dividend of $0.82 per share — an annualized yield of about 2.5%. Institutional ownership remains exceptionally high at roughly 84%, underscoring the stock's role as a core healthcare allocation among major funds. The 52-week range spans from $107.75 to $157.29, placing the current price near the midpoint of that band.

Gilead Sciences (GILD) Business Overview and Competitive Position

Gilead Sciences is a Foster City, California-based biopharmaceutical company with a three-decade track record of developing breakthrough therapies for life-threatening diseases. The company's core franchise is HIV, where flagship oral therapy Biktarvy commands more than 52% of the U.S. treatment market and generates over $3.4 billion in quarterly sales. Gilead's HIV portfolio also includes Descovy for pre-exposure prophylaxis (PrEP) and Yeztugo, the first twice-yearly injectable PrEP option, which is on track to achieve blockbuster status in its first full year on the market. Beyond HIV, Gilead has expanded into oncology through Trodelvy — an antibody-drug conjugate targeting metastatic breast cancer — and maintains a cell therapy business via its Kite Pharma subsidiary. The liver disease portfolio, bolstered by Livdelzi for primary biliary cholangitis, and the antiviral Veklury round out a diversified revenue base that generated approximately $6.96 billion in first-quarter 2026 product sales.

Recent Developments Driving GILD

The most consequential near-term event is Gilead's Q2 2026 earnings report, scheduled for August 4 after market close, which will include an estimated $11.2 billion IPR&D charge from the Arcellx acquisition and other pending transactions. This non-cash charge is expected to produce a significant GAAP loss per share, though the underlying operational performance remains the focal point for investors. In Q1 2026, Gilead delivered an earnings beat with non-GAAP EPS of $2.03 on revenue of $6.96 billion — both ahead of consensus — while raising full-year HIV sales growth guidance to approximately 8%, up from 6%.

On the analyst front, sentiment split in July: Morgan Stanley maintained its Overweight rating with a $166 price target, while BMO Capital stayed at Buy with a $174 target, both citing HIV franchise durability and oncology pipeline potential. Conversely, Leerink Partners downgraded GILD from Outperform to Market Perform on July 20, lowering its price target to $127 and flagging concerns about the HIV PrEP market's competitive landscape. The downgrade trimmed 2031 PrEP sales estimates to $4 billion from $6 billion. Separately, Gilead raised its 2026 Yeztugo sales guidance to approximately $1 billion, up from an initial $800 million forecast, reflecting accelerating market adoption. Trodelvy also secured category 1 NCCN recognition in first-line metastatic triple-negative breast cancer, broadening its addressable patient population.

Trending AI Robots

For traders seeking data-driven insights beyond traditional fundamental analysis, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron hosts hundreds of algorithmic trading bots that actively trade thousands of tickers across various strategies, but only those demonstrating top-tier performance and relevance appear in this featured section. These bots differ in trading style, holding period, and risk profile — spanning short-term swing trading, trend-following, and pattern recognition across equities, ETFs, and forex. By surfacing only the most consistent performers, the Trending AI Robots page helps users quickly identify trading algorithms aligned with their investment approach and market outlook.

2026 Outlook and What Investors Should Watch

Looking ahead, the second half of 2026 presents a series of high-impact milestones for Gilead. The FDA is expected to issue a priority review decision on biclen, a potential new HIV therapy, in August 2026. A PDUFA date for anitocel — the CAR-T therapy acquired through the Arcellx deal — is anticipated in December 2026. Multiple Phase 3 data readouts across the HIV and oncology pipelines are also expected before year-end. On the financial side, investors will scrutinize whether core HIV revenue growth can sustain its momentum amid policy headwinds from Medicaid drug pricing negotiations and proposed Affordable Care Act changes, which management estimates will create an approximate 2% drag. Competitive dynamics in both HIV — where GSK continues to expand its long-acting injectable portfolio — and cell therapy, where Yescarta and Tecartus face mounting pressure, will also shape the stock's trajectory. With a healthy dividend, strong institutional backing, and a pipeline positioned for multiple catalysts, Gilead enters the remainder of 2026 with a complex but potentially rewarding setup.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations